Clinical efficacy of Adefovir dipivoxil combined with Fufang Biejia tablets in treating decompensated cirrhosis in hepatitis with chronic hepatitis B

Objective To investigate the efficacy and safety of Adefovir dipivoxil combined with Fu fang Bie jia tablets in treating HBV related decompensated cirrhosis.Methods Seventy-eight patients with decompensated cirrhosis of hepatitis B virus infection were randomly assigned to treatment group (42cases) and control group (36 cases) .The assessments of liver function, Child-Pugh scores and reduction of serum HBV DNA from baseline were performed at week 48.Results There were statistically significant difference in liver function, Child-Pugh scores and reduction of HBV DNA from baseline (copies/ml) at week 48 between the two groups (P<0.01) .The decreased value of spleen thickness and liver fibrosis index of the treatment groups were more obvious than those of the control group (P<0.01) .Conclusion Adefovir dipivoxil combined with Fu fang Bie jia tablets in treating HBV related-active cirrohosis can significantly enhance the therapeutic effect of liver fibrosis and can coordinately improve the liver function, and provide safety in clinical application.